SynthesisOncotarget2016
Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 5 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Pooled it
- Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.Journal of cancer research and clinical oncology · 2020Pooled it
- Pooled it
- The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.PloS one · 2017Pooled it
- The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis.Technology in cancer research & treatmentPooled it
- Human Papillomavirus Type and Viral Load in Relation to Circulating Cell-Free Tumour HPV DNA Level and Survival in Cervical Cancer.Molecular diagnosis & therapy · 2025Article
- Biologically Active Benzimidazole Hybrids as Cancer Therapeutics: Recent Advances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Deciphering the interplay: circulating cell-free DNA, signaling pathways, and disease progression in idiopathic pulmonary fibrosis.3 Biotech · 2025Review
- Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review).Oncology letters · 2024Review
- Advancements in Heart Transplantation: Donor-Derived Cell-Free DNA as Next-Generation Biomarker.Cureus · 2024Review
- Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.BMC pulmonary medicine · 2023Article
- Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation.International journal of molecular sciences · 2023Review
- Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Preoperative cell-free DNA concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma.Contemporary oncology (Poznan, Poland) · 2023Article
- Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.Thoracic cancer · 2022Article
- Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.Heliyon · 2022Article
- Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers.Cancers · 2022Review
- Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.Frontiers in oncology · 2022Article
- Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.Molecular oncology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating cell-free DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response and survival for cancer patients. Several studies have assessed the prognostic and predictive value of cfDNA in non-small cell lung cancer (NSCLC). However, these studies were often small and reported varying results. To address this issue, a meta-analysis was carried out. A total of 22 studies involving 2518 patients were subjected to the final analysis. Our results indicated that NSCLC patients with higher cfDNA concentration had shorter median progression-free survival (PFS) and overall survival (OS) time. In addition, high levels of cfDNA were significantly associated with poor PFS (hazard ratio or HR, 1.32; 95% CI, 1.02-1.71) and OS (HR, 1.64; 95% CI, 1.26-2.15). With respect to tumor specific mutations, we failed to reveal significant differences for PFS (HR, 1.30; 95% CI, 0.66-2.56) and OS (HR, 1.05; 95% CI, 0.49-2.25) when NSCLC patients were grouped according to KRAS genotype detected in cfDNA. However, NSCLC patients which harbored EGFR activating mutation in cfDNA had a greater chance of response to EGFR-TKIs (odds ratio or OR, 1.96; 95% CI, 1.59-2.42). No significant publication bias was detected in this study. In conclusion, cfDNA could act as a prognostic and predictive biomarker for patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.